First Horizon Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

First Horizon Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-714	Closed	-$31.1K	–	2475
2023 Q3	$31.1K	Buy	714 +338	+90%	+$12.1K	﹤0.01%	1070
2023 Q2	$13.6K	Hold	376	–	–	﹤0.01%	1424
2023 Q1	$14K	Hold	376	–	–	﹤0.01%	1413
2022 Q4	$17K	Sell	376 -98	-21%	-$6.34K	﹤0.01%	1310
2022 Q3	$32K	Buy	474 +96	+25%	+$7.1K	﹤0.01%	1041
2022 Q2	$25K	Buy	+378	New	+$24K	﹤0.01%	1210
2022 Q1	–	Sell	-11	Closed	-$1K	–	2390
2021 Q4	$1K	Hold	11	–	–	﹤0.01%	2194
2021 Q3	$1K	Buy	+11	New	+$1.77K	﹤0.01%	2221

Other funds holding MRTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

First Horizon Advisors's MRTX Position: Q4 2023 in Review

First Horizon Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 714 shares — an estimated $31.1K sold.

First Horizon Advisors first reported a position in MRTX in Q3 2021 and held it in 8 quarters. The position peaked at $32K in Q3 2022. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

First Horizon Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
First Horizon Advisors sold 714 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $31.1K.
First Horizon Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
First Horizon Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $32K in Q3 2022.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on First Horizon Advisors's 13F filing for Q4 2023, filed 6 Feb 2024.